The efficacy and safety of tenapanor plus PBs in Chinese patients are still unclear. Therefore, we aim to conduct a real-world study to explore the effect of combining two drugs with different mechanisms on hyperphosphatemia management.This real-world study will enroll hemodialysis patients with hyperphosphatemia who are on PBs therapy.
The subject has provided written informed consent prior to the initiation of any study-related activities.
Male or female subjects aged ≥18 years at the time of signing the informed consent form.
The subject is receiving regular maintenance hemodialysis (3 times per week, 4 hours per session) for at least 3 months.
The patient has been on phosphate binder therapy for at least 3 weeks, with a stable dose.
Hypersensitivity to Tenapanor or any excipients of the formulation.
History of diarrhea within 1 week prior to the start of treatment. Diarrhea is defined as a Bristol Stool Form Scale (BSFS) score ≥6 (i.e., mushy or liquid stools with no solid pieces), a daily bowel movement frequency ≥3 times, and a duration of ≥2 days.
Life expectancy < 6 months.
Expected or planned kidney transplantation during the study period.
Hemodialysis patients with hyperphosphatemia despite the use of phosphate binders
Cohort
Prospective
Not listed
The proportion of patients with serum phosphorus levels <5.5 mg/dL
The proportion of patients with serum phosphorus levels <5.5 mg/dL
The proportion of patients achieving the target serum phosphorus level (<4.5 mg/dL)
The change from baseline in serum phosphorus levels
The dosage and quantity of Tenapanor and phosphate binders used by patients
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
